Short answer
USANA HEALTH SCIENCES INC (USNA) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). USANA reported third-quarter fiscal 2026 results for the period ended October 3, 2026.
USANA HEALTH SCIENCES INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- USANA reported third-quarter fiscal 2026 results for the period ended October 3, 2026
- Management Commentary provides additional operating context through Exhibit 99.2
- Investor conference call scheduled for management remarks and analyst Q&A
- Financial results and commentary available through Exhibits 99.1 and 99.2 and USANA’s website
Item 7.01 · Regulation FD Disclosure
- Item 7.01 incorporates the Item 2.02 disclosure and Item 9.01 exhibits
- Investor significance depends on the earnings information and supporting exhibits referenced elsewhere in the filing
Item EX-99.1 · Exhibit EX-99.1
- Q3 net sales $206M, down 4% year over year, with Core Nutritional and Rise declines outweighing Hiya growth
- Net loss $(5.6)M and diluted EPS $(0.30), while adjusted EBITDA fell 13% to $12.1M
- Hiya subscribers rose 18% sequentially to 195,500, but higher acquisition spending pressured margins
- Core Nutritional active customers fell 8% year over year to 356,000, highlighting the primary recovery challenge
- FY2026 outlook reduced to net sales approaching $900M, adjusted EBITDA $77M, and diluted EPS $(0.90)
Item EX-99.2 · Exhibit EX-99.2
- Q3 net sales $206M, down 4% year over year, with Core Nutritional and Rise declines outweighing Hiya growth
- Net loss $5.6M, diluted EPS $(0.30), and Adjusted EBITDA $12.1M, down 13% year over year
- Core Nutritional active customers fell 8% to 356,000, signaling continued pressure on USANA’s core direct-selling model
- Hiya subscribers rose 18% sequentially to 195,500, but higher acquisition spending pressured near-term profitability
- 2026 outlook reduced: consolidated sales approaching $900M, net loss $(16)M, adjusted EPS $0.55, and Adjusted EBITDA $77M
- Balance sheet remains a strategic cushion: $179M cash, zero debt, and $36M year-to-date free cash flow
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other USANA HEALTH SCIENCES INC 8-K filings
Get the next USNA 8-K as it lands
Follow USNA for push alerts, or ask the research agent what this filing means.